Mission Therapeutics Limited
MISSION Therapeutics was founded in 2011. The company focuses on the biology of the DNA damage response (DDR) processes in cancer, optimising small molecule drugs to exploit synthetic lethality to selectively kill high unmet-need tumour types. Targeting deubiquitylating enzymes (DUBs) involved in regulating the DDR, MISSION has built an extensive proprietary biology and chemistry platform (Ubi-Sphere™) to support its discovery of inhibitors of DUBs. The application of DUB inhibitors extends across several therapeutic areas including neurodegeneration and infectious disease. The company is based at the Babraham Research Campus, Cambridge, UK.